HIV Medicine · 2018 · 21 citations · 31 references
Life SciencesInfectious DiseasesPharmacologyAntimicrobial ResistanceMolecular VirologyPharmacogeneticsAntiretroviral TherapyAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyHiv EpidemiologyResistance EpidemiologyAntiviral Resistance MutationsDrug Resistance MutationsHiv Drug Resistance EpidemiologyIntegrase Inhibitor ResistanceIntegrase Strand Transfer InhibitorsLogistic RegressionResistance Mutation AnalysisResistance-associated Mutations
OBJECTIVES: The aim of the study was to analyse the prevalence of integrase resistance mutations in integrase strand transfer inhibitor (INSTI)-experienced HIV-1-infected patients and its predictors. METHODS: test and predictors of resistance were analysed by logistic regression. RESULTS: We included 462 genotypes from INSTI-exposed individuals: 356 'INSTI-failing' patients and 106 'previously INSTI-exposed' patients (obtained a median of 42 weeks after INSTI discontinuation [interquartile range (IQR) 17-110 weeks]). Overall, at least low-level resistance (LLR) to any INSTI (Stanford 8.5 algorithm) was detected in 198 (42.9%) cases. The most frequent INSTI resistance mutation was N155H, followed by Q148H/K/R, G140A/C/S, E138A/K/T and Y143C/H/R. Y143R and E138A were more prevalent in viral subtype B versus non-B [5.2 versus 1.5%, respectively (P = 0.04), and 3.1 versus 0%, respectively (P = 0.02)]. Overall, the Q148H/K/R plus G140A/C/S and/or E138A/K/T pattern, defining an intermediate level of resistance to DTG, was detected in 70 (15%) cases. Independent predictors of at least LLR to any INSTI were current use versus past use of INSTIs, a lower genotypic sensitivity score (GSS) for contemporary antiretroviral drugs used, and having an integrase sequence obtained in calendar year 2016 as compared to 2008-2009. CONCLUSIONS: The results support integrase resistance testing in INSTI-experienced patients. Emergence of INSTI resistance is facilitated by the reduced genetic barrier of the regimen as a consequence of resistance to companion drugs. However, INSTI resistance may become undetectable by standard population sequencing upon INSTI discontinuation.
31
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Huldrych F. Günthard, Michael S. Saag, Constance A. Benson et al. · JAMA · 2016 · 656 citations · Full text
Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 620 citations
Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text